In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease-Reference-Cited by-同舟云学术

In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease

Published:2018-10 Issue:10 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kwon Byoung Soo¹,Kim Mi-Na²^ORCID,Sung Heungsup²,Koh Younsuck¹,Kim Woo-Sung¹,Song Jin-Woo¹,Oh Yeon-Mok¹,Lee Sang-Do¹,Lee Sei Won¹,Lee Jae-Seung¹,Lim Chae-Man¹,Choi Chang-Min¹,Huh Jin-Won¹,Hong Sang-Bum¹,Park Sojung³,Shim Tae Sun¹,Chong Yong Pil⁴,Jo Kyung-Wook¹

Affiliation:

1. Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

2. Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

3. Department of Pulmonary, Allergy, and Critical Care Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, South Korea

4. Department of Infectious Diseases, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

Abstract

Although it is known that the in vitro MICs of rifampin and ethambutol are poorly correlated with the clinical response in Mycobacterium avium complex (MAC) lung disease (MAC-LD), evidence for this is limited. This study investigated the association between treatment outcome and the in vitro MICs of rifampin and ethambutol in patients with MAC-LD.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00491-18

Reference40 articles.

1. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review

2. Increasing Trend of Isolation of Non-Tuberculous Mycobacteria in a Tertiary University Hospital in South Korea

3. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease

4. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives

5. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Drug Susceptibility of Non-Tuberculous Mycobacteria (NTM) in a Referral Hospital in Rome from 2018 to 2023;Microorganisms;2024-08-08

2. Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex–pulmonary disease in patients unsuitable for standard treatment regimen;International Journal of Antimicrobial Agents;2024-02

3. Treatment of Mycobacterium avium complex pulmonary disease;Journal of the Korean Medical Association;2024-01-10

4. Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection;Scientific Reports;2023-11-23

5. In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022;Journal of Antimicrobial Chemotherapy;2023-10-21